Search research articles
Contact Us
Filters
Showing results (161-170 of 178) with videos related to
Page
of 18
Sort By:
Plos One
|
May 7, 2025
Arsenic exposure is associated with elevated sweat chloride concentration and airflow obstruction among adults in Bangladesh: A cross-sectional study
Mi-Sun S Lee, Crystal M North, Irada Choudhuri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 24, 2018
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
Jessica J Lin, Viola W Zhu, Adam J Schoenfeld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 11, 2022
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer
Joshua K Sabari, Vamsidhar Velcheti, Kazuhide Shimizu, et al.
JCO Oncology Practice
|
July 12, 2023
Integrated Radiology, Pathology, and Pharmacy Program to Accelerate Access to Osimertinib
Ibiayi Dagogo-Jack, Amanda Manoogian, Nicholas Jessop, et al.
JCO Precision Oncology
|
August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer
Zofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.
The New England Journal of Medicine
|
June 4, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1
Mark M Awad, Ryohei Katayama, Michele McTigue, et al.
Cancer Discovery
|
December 7, 2011
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
Anthony C Faber, Ryan B Corcoran, Hiromichi Ebi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2020
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study
Sarah Waliany, Shambo Guha Roy, Federica Pecci, et al.
Cancer Discovery
|
January 14, 2026
Circulating Tumor Cells Predict Response to the DLL3-targeting Bispecific Antibody Tarlatamab
Avanish Mishra, Catherine B Meador, Kruthika Kikkeri, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 178) with videos related to
Sort By:
Page
of 18
Plos One
|
May 7, 2025
Arsenic exposure is associated with elevated sweat chloride concentration and airflow obstruction among adults in Bangladesh: A cross-sectional study
Mi-Sun S Lee, Crystal M North, Irada Choudhuri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 24, 2018
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
Jessica J Lin, Viola W Zhu, Adam J Schoenfeld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 11, 2022
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer
Joshua K Sabari, Vamsidhar Velcheti, Kazuhide Shimizu, et al.
JCO Oncology Practice
|
July 12, 2023
Integrated Radiology, Pathology, and Pharmacy Program to Accelerate Access to Osimertinib
Ibiayi Dagogo-Jack, Amanda Manoogian, Nicholas Jessop, et al.
JCO Precision Oncology
|
August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer
Zofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.
The New England Journal of Medicine
|
June 4, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1
Mark M Awad, Ryohei Katayama, Michele McTigue, et al.
Cancer Discovery
|
December 7, 2011
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
Anthony C Faber, Ryan B Corcoran, Hiromichi Ebi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2020
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study
Sarah Waliany, Shambo Guha Roy, Federica Pecci, et al.
Cancer Discovery
|
January 14, 2026
Circulating Tumor Cells Predict Response to the DLL3-targeting Bispecific Antibody Tarlatamab
Avanish Mishra, Catherine B Meador, Kruthika Kikkeri, et al.
Page
of 18